Medical cannabis authorization and the risk of cardiovascular events : a longitudinal cohort study Arsene Zongo, Cerina Lee, Jason R. B. Dyck, Jihane El‑Mourad, Elaine Hyshka, John G. Hanlon and Dean T. Eurich BMC Cardiovascular Disorders, 2021, 21, 426 doi : 10.1186/s12872-021-02229-6 Abstract Background : Cannabis is increasingly used for therapeutic purpose. However, its safety profile is not well known. This study assessed the risk of cardiovascular-related emergency department (ED) visit and hospitalization in adult patients authorized to use medical cannabis in Ontario, Canada from 2014 to 2017. Methods : This is a longitudinal cohort study of patients who received medical cannabis authorization and followedup in [...]
Lire la suiteScoping Review and Meta-Analysis Suggests that Cannabis Use May Reduce Cancer Risk in the United States Thomas M. Clark Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 413-434. Doi : 10.1089/can.2019.0095 Abstract Introduction:Cannabis smoke contains carcinogens similar to tobacco, in addition to compounds with antitumor activity. Cannabis use reduces the risk of obesity and cannabinoids inhibit chronic inflammation, known causes of cancer. The net effect of Cannabis use on cancer risk is not known. Objective: To examine the association between Cannabis use and cancer risk in the United States. Methods: Identify and analyze published data on cancer risk in Cannabis users. Results: A total of 55 data [...]
Lire la suiteCannabinoid CB2 Receptor Activation Attenuates Fentanyl-Induced Respiratory Depression Carmen A. Zavala, Ana C. Thomaz, Vishakh Iyer, Ken Mackie, and Andrea G. Hohmann Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 389-400. DOI: 10.1089/can.2020.0059 Abstract Introduction : Overdose fatalities associated with the opioid epidemic are predictably attributable to druginduced respiratory depression. In terms of illicit opioid abuse, fentanyl is the synthetic opioid responsible for the largest number of overdose deaths. There is, therefore, an urgent need to identify safe and effective therapeutics that can attenuate fentanyl-induced respiratory depression. Identification of effective alternate analgesic strategies that lessen the respiratory depression associated with narcotics would also help [...]
Lire la suiteCannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression Beth M. Wiese, Erika Liktor-Busa, Aidan Levine, Sarah A. Couture, Spyros P. Nikas, Lipin Ji, Yingpeng Liu, Kenneth Mackie, Alexandros Makriyannis, Tally M. Largent-Milnes and Todd W. Vanderah Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 401-412. Doi : 10.1089/can.2020.0076 Abstract Introduction : An escalating number of fatalities resulting from accidental opioid overdoses typically attributed to respiratory depression continue to define the opioid epidemic. Opioid respiratory depression results from a decrease in reflexive inspiration within the preBo¨ tzinger complex in the brainstem. Objective : Cannabinoid receptor agonism is reported to enhance opioid analgesia, yet whether cannabinoids enhance [...]
Lire la suiteL’évaluation et l’efficacité des psychothérapies psychanalytiques et de la psychanalyse The evaluation and the efficacy of psychoanalytical therapies and psychoanalysis Thomas Rabeyron L’Évolution Psychiatrique, 2021, 86, 3, 455-488 Doi : 10.1016/j.evopsy.2020.07.003 Résumé Objectif. – Cet article propose une revue de littérature concernant l’évaluation et l’efficacité des psychothérapies psychanalytiques et de la psychanalyse (PPP). Méthode. – Après avoir proposé une vue d’ensemble de l’évaluation des psychothérapies, nous reprenons les travaux portant sur l’évaluation empirique et quantitative des PPP avant de nous centrer sur leur évaluation qualitative et processuelle.Résultats. – Les résultats des études menées en ce domaine démontrent que les psychothérapies sont efficaces aussi bien sur le court [...]
Lire la suiteReal life Experience of Medical Cannabis Treatment in Autism : Analysis of Safety and Efficacy Lihi Bar-Lev Schleider, Raphael Mechoulam, Naama Saban, Gal Meiri & Victor Novack Scientific Reports, Nature.com, 2019, 9, 200, 1-7 Doi : 10.1038/s41598-018-37570-y There has been a dramatic increase in the number of children diagnosed with autism spectrum disorders (ASD) worldwide. Recently anecdotal evidence of possible therapeutic effects of cannabis products has emerged. The aim of this study is to characterize the epidemiology of ASD patients receiving medical cannabis treatment and to describe its safety and efficacy. We analysed the data prospectively collected as part of the treatment program of [...]
Lire la suiteLe Bus des femmes Prostituées. Histoire d'une mobilisation Anne Coppel, Lydia Braggiotti, Malika Amaouche Editions Anamosa, 2020, 152 pages N° ISBN : 979-10-95772-83-5 https://anamosa.fr/livre/le-bus-des-femmes/ En pleine épidémie de sida, des prostituées interpellent les pouvoirs publics sur leur santé et les conditions d’exercice de leur métier. Leur action, contemporaine de la création d’Act Up-Paris, conduira à la création du Bus des femmes en 1990. Un document historique rarissime qui témoigne de l’histoire des mobilisations citoyennes, un exemple unique de class action chez les prostituées. En 1990 à Paris, alors que l’épidémie de sida produit chaque jour plus de ravages, des prostituées se mobilisent et interpellent les pouvoirs publics. [...]
Lire la suiteCurrent state of evidence of cannabis utilization for treatment of autism spectrum disorders Rumi Agarwal, Shanna L. Burke and Marlaina Maddux BMC Psychiatry, 2019, 19, 328 Doi : 10.1186/s12888-019-2259-4 Abstract The core symptoms and co-morbidities associated with autism spectrum disorders (ASD) affect daily living and quality of life. Existing pharmacological interventions are only able to attenuate some related symptoms but are unable to address the underlying etiologies associated with ASD. Anecdotal evidence, which claims benefit from the use of cannabis to treat symptoms among this population, has been gaining popularity as families seek solutions. This paper analyzed recent peer-reviewed literature to identify the current state of [...]
Lire la suiteThe effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD) Charlotte M. Pretzsch, Bogdan Voinescu, Maria A. Mendez, Robert Wichers, Laura Ajram, Glynis Ivin, Martin Heasman, Steven Williams, Declan GM Murphy, Eileen Daly and Gráinne M. McAlonan Journal of Psychopharmacology, 2019, Vol. 33, (9), 1141–1148 Doi : 10.1177/0269881119858306 Abstract Background : The potential benefits of cannabis and its major non-intoxicating component cannabidiol (CBD) are attracting attention, including as a potential treatment in neurodevelopmental disorders such as autism spectrum disorder (ASD). However, the neural action of CBD, and its relevance to ASD, remains [...]
Lire la suiteEffects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, 2019, volume 10, Article 1146, 1-9. doi : 10.3389/fneur.2019.01145 Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]
Lire la suite